CA9 and colon carcinoma: [89Zr]ZrDFOSq-girentuximab was administered to HT29 tumour-bearing BALB/c mice (a high CA-IX expressing human colon carcinoma cell line)(Carlin et al. 2010; Mahalingam et al. 2018) and PET images were acquired at 24, 48 to 144 h post injection (Fig. 4a).